Evaluating the Safety and Tolerability of the Combination of Dabrafenib, Trametinib and Palliative Radiotherapy in Patients with Metastatic BRAF V600E/K Mutation-positive Cutaneous Melanoma

Authors :: D. Christie
R. Wolfe
Gerald B Fogarty
Matteo S. Carlino
Narelle Williams
V. Estall
Elizabeth J. Paton
Mark Shackleton
Mark B. Pinkham
J.L. Smith
Tim Wang
Victoria Steel
Bryan Burmeister
T.L.T. Phuong
Source :: International Journal of Radiation Oncology*Biology*Physics. 108:S133-S134
Publication Year :: 2020
Publisher :: Elsevier BV, 2020.

Subjects :: Oncology
Trametinib
Cancer Research
medicine.medical_specialty
Radiation
business.industry
Dabrafenib
BRAF V600E
Tolerability
Palliative radiotherapy
Internal medicine
Mutation (genetic algorithm)
Cutaneous melanoma
medicine
Radiology, Nuclear Medicine and imaging
In patient
business
medicine.drug

Full Text Access

Tools